11.0374
13.1883
1
1 Lakh
Investment declined to₹ 10000
Monthly SIP Declined toSuitability:
This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.
Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.
Taxability of earnings:
Capital gains
Dividends
Please wait...
Please wait...
| YTD | 1-Day | 1-W | 1-M | 3-M | 6-M | 1-Y | 3-Y | 5-Y | 7-Y | 10-Y | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct-G | -12.55 | -0.28 | 0.34 | -2.85 | -8.17 | -12.55 | -8.24 | -- | -- | -- | -- |
| S&P BSE Healthcare TRI* | -16.82 | 0.62 | 0.34 | -2.06 | -10.68 | -16.82 | -15.08 | -- | -- | -- | -- |
| Equity: Sectoral-Pharma* | -15.18 | 0.70 | 0.57 | -1.35 | -9.36 | -15.18 | -11.74 | -- | -- | -- | -- |
As on 30-Jun-2022
* As on 01-Jul-2022
| Fund name | Rating | Launch Date | 1-Year Return | 3-Year Return | 5-Year Return | Expense Ratio | Assets (Cr) |
|---|---|---|---|---|---|---|---|
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Direct Plan | Invest Online | Oct-20 | -8.24 | -- | -- | 0.46% | 157 | |
| Nippon India Pharma Fund - Direct Plan | Jan-13 | -13.45 | 23.60 | 16.40 | 1.04% | 4,516 | |
| ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan | Invest Now | Jul-18 | -11.23 | 24.31 | -- | 1.23% | 2,316 | |
| Mirae Asset Healthcare Fund - Direct Plan | Invest Online | Jul-18 | -9.01 | 28.10 | -- | 0.64% | 1,692 | |
| SBI Healthcare Opportunities Fund - Direct Plan | Invest Online | Jan-13 | -12.50 | 23.40 | 11.02 | 1.07% | 1,638 |
| Best Performance | Worst Performance | |||
|---|---|---|---|---|
| Return (%) | Period | Return (%) | Period | |
| Week | 4.83 | 17-Jun-2022 - 24-Jun-2022 | -5.14 | 02-May-2022 - 10-May-2022 |
| Month | 12.43 | 19-Mar-2021 - 20-Apr-2021 | -9.42 | 11-Apr-2022 - 11-May-2022 |
| Quarter | 17.66 | 18-Mar-2021 - 17-Jun-2021 | -11.74 | 17-Mar-2022 - 17-Jun-2022 |
| Year | 26.57 | 02-Nov-2020 - 02-Nov-2021 | -9.94 | 17-Jun-2021 - 17-Jun-2022 |
| Mean | Std Dev | Sharpe | Sortino | Beta | Alpha | |
|---|---|---|---|---|---|---|
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct-G | -- | -- | -- | -- | -- | -- |
| S&P BSE Healthcare TRI* | 20.37 | 22.36 | 0.75 | 1.50 | -- | -- |
| Equity: Sectoral-Pharma* | 23.61 | 20.44 | 0.99 | 2.00 | 0.89 | 5.06 |
The Risk Measures have been calculated using calendar month returns for the last three years.
As on
* As on 30-Jun-2022
Please wait...
| Number of Stocks | 44 |
| Top 10 Stocks (%) | 51.65 |
| Top 5 Stocks (%) | 39.41 |
| Top 3 Sectors (%) | 99.98 |
| Portfolio P/B Ratio | 110.29 |
| Portfolio P/E Ratio | 968.33 |
| Fund | Category | |
|---|---|---|
| Average Mkt Cap (Rs Cr) | 1,58,289 | 55,629 |
| Giant (%) | 42.37 | 19.21 |
| Large (%) | 31.05 | 38.04 |
| Mid (%) | 25.98 | 35.58 |
| Small (%) | 0.60 | 7.07 |
| Tiny (%) | -- | 0.73 |
Please wait...
| Company | Sector | P/E | 3Y High | 3Y Low | % Assets | |
|---|---|---|---|---|---|---|
|
Sun Pharmaceutical Industries | Healthcare | 60.61 | 11.48 | 0.00 | 11.00 |
|
|
Dr. Reddy's Lab | Healthcare | 33.43 | 9.96 | 0.00 | 7.75 |
|
|
Cipla | Healthcare | 30.42 | 7.32 | 0.00 | 7.32 |
|
|
Divi's Laboratories | Healthcare | 32.68 | 9.72 | 0.00 | 7.26 |
|
Apollo Hospitals | Healthcare | 50.82 | 8.00 | 0.00 | 6.08 |
|
Johnson & Johnson | Healthcare | -- | 5.02 | ||
|
|
Pfizer INC | Healthcare | -- | 3.12 | ||
|
|
Laurus Labs | Healthcare | 30.33 | 3.27 | 0.00 | 2.78 |
|
|
Max Healthcare Institute | Healthcare | 57.69 | 2.76 | 0.00 | 2.76 |
|
|
AbbVie Inc | Healthcare | -- | 2.68 | ||
|
|
Merck & Co Inc (US) | Healthcare | -- | 2.39 | ||
|
|
Aurobindo Pharma | Healthcare | 11.57 | 4.59 | 0.00 | 2.37 |
|
|
Thermo Fisher Scientific Inc | Healthcare | -- | 2.36 | ||
|
|
Abbott Laboratories | Healthcare | -- | 2.21 | ||
|
|
Torrent Pharmaceuticals | Healthcare | 63.59 | 2.34 | 0.00 | 2.19 |
|
|
Lupin | Healthcare | -- | 4.30 | 0.00 | 2.14 |
|
|
Biocon | Healthcare | 57.70 | 3.21 | 0.00 | 2.13 |
|
|
Novartis AG (ADS/ADR) | Healthcare | -- | 2.08 | ||
|
|
Ipca Laboratories | Healthcare | 26.20 | 2.65 | 0.00 | 1.93 |
|
|
Danaher Corporation | Healthcare | -- | 1.82 | ||
|
|
Bristol-Myers Squibb Co | Healthcare | -- | 1.74 | ||
|
|
Fortis Healthcare | Healthcare | 32.06 | 1.92 | 0.00 | 1.64 |
|
|
Amgen Inc. (USA) | Healthcare | -- | 1.51 | ||
|
|
Medtronic | Healthcare | -- | 1.44 | ||
|
|
Abbott India | Healthcare | 50.77 | 1.53 | 0.00 | 1.43 |
Indicates an increase or decrease or no change in holding since last portfolio
Indicates a new holding since last portfolio
As on 31-May-2022
— Bhavesh Jain since 01-Oct-2021
Education: Mr. Jain is a MMS (Finance) from Mumbai University.
Experience: Prior to joining Edelweiss Mutual Fund he was previously associated with Edelweiss Securities Limited as SGX Nifty Arbitrage Trader.
Funds Managed:
The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors.
| Min. Investment (₹) | 5,000 |
| Min. Addl Investment (₹) | 500 |
| Min. SIP Investment (₹) | 500 |
| Min. No of Cheques | 12 |
| Min. Withdrawal (₹) | 500 |
| Min. Balance (₹) | -- |
| Lock-in Period | Not Applicable |
| Exit Load | 0 |
| Fund House: | Edelweiss Mutual Fund |
| Launch Date: | 26-Oct-2020 |
| Return Since Launch: | 8.75% |
| Benchmark: | MSCI India Domestic & World HC 45 Index |
| Riskometer: | Very High |
| Type: | Open-ended |
| Assets: | ₹ 157 Cr (As on 31-May-2022) |
| Expense: | 0.46% (As on 31-May-2022) |
| Risk Grade: | -- |
| Return Grade: | -- |
| Turnover: | -- |
AMC: Edelweiss Asset Management Ltd.
Address: Edelweiss House Off C.S.T. Road, Kalina Mumbai - 400098
Phone: +91 22 4093 3400
Fax: +91 22-40979878
Website: http://www.edelweissmf.com
Registrar & Transfer Agent: KFin Technologies Ltd.
Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016
Phone: 040-44857874
Email: [email protected]
Website: www.karvymfs.com
You have reserved a spot
Fri, 08-Jul-2022
12:30 PM - 12:40 PM